INKON Life(SZ:300143) Zheng Quan Ri Bao·2025-04-29 05:12Core Viewpoint - 盈康生命科技股份有限公司 continues to demonstrate steady growth in 2024, driven by its differentiated and AI-enabled strategies, enhancing operational efficiency and profitability [2][3]. Financial Performance - In Q1 2025, the company achieved revenue of 409 million yuan, a year-on-year decrease of 1.73%; net profit attributable to shareholders was 30 million yuan, an increase of 14.4%; and non-recurring net profit was also 30 million yuan, up 25.77% [2]. - For the full year 2024, the company reported revenue of 1.559 billion yuan, a year-on-year increase of 6.01%, and a net profit of 115 million yuan, up 14.92% [2]. - The compound annual growth rates for revenue and net profit over the past five years were 23.9% and 14.9%, respectively, indicating a trend of high-quality development [2]. AI Empowerment and Innovation - Since 2021, the company has strategically positioned itself in the "medical + AI" sector, establishing itself as a pioneer in group AI deployment within the industry [3]. - The company embraces a "three-full" concept of AI, focusing on full participation, full coverage, and full process, to enhance diagnostic capabilities, patient experience, and operational management [3]. - In 2024, the company reported an 8.9% increase in revenue per capita and a 20.2% increase in profit per capita, while the period expense ratio decreased by 0.8 percentage points [3]. Differentiated Development Path - The company has driven business growth through a differentiated approach, with the medical services segment generating revenue of 1.19 billion yuan in 2024, of which tumor-related revenue was 380 million yuan, accounting for 31.9% of medical service revenue, an increase of 17% year-on-year [4]. - The company has developed a "three-special" system focusing on specialized departments, diseases, and expertise, integrating medical innovation to enhance user experience and meet diverse needs [4]. External Growth Strategy - In 2025, the company plans to deepen its tumor medical specialty through external growth, announcing a cash acquisition of 51% of Changsha Kexin Tumor Hospital for 357 million yuan [6]. - Changsha Kexin, established in 2015, is a tertiary tumor specialty hospital with 420 beds and advanced radiotherapy equipment, performing over 8,000 minimally invasive surgeries annually [6]. - The acquisition is part of the company's strategy to enhance its regional medical center layout and is expected to significantly improve its technical depth and service breadth in the tumor specialty field, thereby strengthening its profitability [6].